Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control numb Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449/PTO

Sheet

TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1	of	2	

Complete if Known			
Application Number	09/921,143		
Filing Date	August 3, 2001		
First Named Inventor	Timothy A. COLEMAN		
Art Unit	1636		
Examiner Name	QIAN, Celine X.		
Attorney Docket Number	1488.100000N/PAJ/PAC		

			U.S. PATENT DO		
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
IIIIIII	110.	Number-Kind Code ^{2 (If Known)}			or Relevant Figures Appea
CQ	US10	6,297,238	10/02/2001	Doyle et al.	
1	USII	6,515,105	02/04/2003	Alitalo et al.	
	US12	6,660,744	12/09/2003	Hirst et al.	
	US13	6,713,474	03/30/2004	Hirst et al.	
	US14	6,764,820	07/20/2004	Ferrell et al.	
	US15	6,824,777	11/30/2004	Alitalo et al.	
	US16	2002/0013261 A1	01/31/2002	Pawliuk et al.	
	US17	2002/0019350 A1	02/14/2002	Levine et al.	
	US18	2002/0034501 A1	03/21/2002	Pawliuk et al.	
	US19	2002/0086004 A1	07/04/2002	Adnot et al.	
	US20	2002/0111362 A1	08/15/2002	Rubinfeld, Joseph	
	US21	2002/0151489 A1	10/17/2002	Gravereaux et al.	
	US22	2002/0155421 A1	10/24/2002	Kearney et al.	
	US23	2002/0156081 A1	10/24/2002	Hirst et al.	
	US24	2003/0103943 A1	06/05/2003	Rosengart et al.	
	US25	2003/0125523 A1	07/03/2003	Alitalo et al.	
	US26	2003/0153752 A1	08/14/2003	Hirst et al.	
	US27	2003/0165464 A1	09/04/2003	Enholm et al.	
V	US28	2003/0180286 A1	09/25/2003	Carmeliet et al.	
	US29	2003/0187001 A1	10/02/2003	Calderwood et al.	

		. Fo	REIGN PATENT DO	OCUMENTS	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)]		Τ [¢]
CQ	FP13	WO 00/21560 A1	04/20/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY	
	FP14	WO 00/24412 A2	05/04/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY	
	FP15	WO 00/58511 A1	10/05/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY; University of Pittsburgh of the Commonwealth System of Higher Education	
	FP16	WO 00/61186 A1	10/19/2000	Weichselbaum, Ralph R.	
7/	FP17	WO 00/62798 A2	10/26/2000	St. Elizabeth's Medical Center, Inc.	
V	FP18	WO 01/52904 A2	07/26/2001	Gill, Parkash S.	

576305.1

Examiner Signature	/Celine Qian/	Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 'Applicants unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Umos; U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ubstitute for form 1449/PTO

TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known					
Application Number 09/921,143					
Filing Date	August 3, 2001				
First Named Inventor	Timothy A. COLEMAN				
Art Unit	1636				
Examiner Name	QIAN, Celine X.				
Attorney Docket Number	1488.100000N/PAJ/PAC				

			U.S. PATENT DO	CUMENTS	
Examiner Initials	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
minais	No.	Number-Kind Code ^{2 (If Known)}		Applicant of Cited Document	or Relevant Figures Appear
CQ	US30	2003/0211988 A1	11/13/2003	Epstein, Stephen E.	
Ī	US31	2004/0002140 A1	01/01/2004	Gilbert et al.	
	US32	2004/0006083 A1	01/08/2004	Hirst et al.	
	US33	2004/0031067 A1	02/12/2004	Herlyn et al.	
$ \overline{} $	US34	2004/0248781 A1	12/09/2004	Kerbel, Robert	• •
$-\Lambda$	US35	2005/0118180 A1	06/02/2005	Rubinfeld, Joesph	

	.		REIGN PATENT DO		
Examiner Initials*	Cite No.1			Name of Patentee or Applicant of Cited Document	
	ŀ	Country Code ³ Number ⁴ Kind Code ³ (if known)			T۴
CQ	FP19	WO 03/000009 A2	01/03/2003	Ludwig Institute for Cancer Research; Flanders Interuniversity Institute for Biotechnology	
CQ	FP20	WO 03/015755 A1	02/27/2003	Ramot At Tel Aviv University Ltd.	
					-

576305.1

Examiner Signature Celine Qian Distriction Claim Clai	Date Considered
--	--------------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2005.
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO NINTH SUPPLEMENTAL Synformation disclosure STATEMENT BY APPLICANT (Use as many sheets as necessary)

of

Complete	if Known
Application Number	09/921,143
Filing Date	August 3, 2001
First Named Inventor	Coleman, Timothy A.
Art Unit	1636
Examiner Name	Qian, Celine X.
Attorney Docket Number	1488.100000N/HCC/PAC

1				U.S. PATENT DO	CUMENTS	
Examine Initials	Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
	(n)trats	NO.	Number-Kind Code ^{2 (IFE,most)}	MM-DD-TTTT	Applicant of Cited Document	or Relevant Figures Appear
ı	CQ	USI	5,652,225	07/29/1997	Isner	
		US2	5,661,133	08/26/1997	Leiden and Barr	
		US3	5,693,622	12/02/1997	Wolff et al.	
ı		US4	5,792,453	08/11/1998	Hammond et al.	
ı		US5	6,121,246	09/19/2000	Isner	
I		US6	6,361,946 B1	03/26/2002	Alitalo and Joukov	
I	•	US7	6,451,764 B1	09/17/2002	Lee and Wood	
I	7/	US8	6,645,933 B1	11/11/2003	Alitalo and Joukov	
I	V	US9	2006/0014252 A1	01/19/2006	Lyman	
ļ						
ŀ						
ŀ	<u> </u>					
ł				 		-
ŀ			_	 		
1			i	I		

		FC	DREIGN PATENT D	OCUMENTS		••
Examiner Initials*	Cite No.'	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	7
CQ	FP1	EP 0 186 084 A2	07/02/1986	Merck & Co. Inc.	Appear	Ħ
1	FP2	JP 64-38100 A	02/08/1989	Toray Ind. Inc.		Г
	FP3	JP 2-117698 A	05/02/1990	Ajinomoto KK and Toray Ind. Inc.		
	FP4	EP 0 399 816 A1	11/28/1990	Merck & Co. Inc.		
	FP5	WO 94/11506 Å1	05/26/1994	Arch Development Corporation		
	FP6	WO 97/17442 A1	05/15/1997	Immunex Corporation		
	FP7	WO 00/45835 A1	08/10/2000	Human Genome Sciences, Inc. and Rosen et al.		•
	FP8	WO 02/11769 A1	02/14/2002	Human Genome Sciences, Inc. and Coleman		
V	FP9	WO 02/083704 A1	10/24/2002	Human Genome Sciences, Inc. and Rosen et al.	·	

Examiner	/Celine Qian/	Date	7
Signature	/Celine Qian/	Considered	- [

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant, "Applicant's unique citation designation number (optional), "See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the hwo-tester code (WIPO Standard ST.3), "For Japanese petent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbots as indicated on the document under WIPO Standard ST.10 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentilality is governed by 35 USC. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Equivalent of Form PTO/SB/08A (07-05) Approved for use Drough 07/31/2005.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are regulard to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
			embim . v	Application Number	09/921,143	
			WENTAL	Filing Date	August 3, 2001	
INFO	RMA'	TION	DISCLOSURE	First Named Inventor	Coleman, Timothy A.	•
STAT	EME:	NT BY	APPLICANT	Art Unit	1636	•
	(Use as	many she	ets as necessary)	Examiner Name	Qian, Celine X.	•
Sheet	2	of	2	Attorney Docket Number	1488.100000N/HCC/PAC	-

<u>57</u>						
<u> </u>			U.S. PATENT DO			
Examiner Initials	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lin Where Relevant Pass	
	1.0.	Number-Kind Code ^{2 (tr Kerne)}			or Relevant Figures Appe	
	<u> </u>		ļ			
	 		 	··-	 	
	-				 	
	 					
	 					
						-
	<u> </u>					
	 					
	 					
	 	-				
					 	
			FOREIGN PATENT D			
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where	
		Country Code ² Number ² Kind Code ² (If know	0		Relevant Passages or Relevant Figures Appear	T*
CQ	FP10	WO 02/083849 A2	10/24/2002	Human Genome Sciences, Inc. and Rosen et al.		
	FPII	WO 02/083850 A2	10/24/2002	Human Genome Sciences, Inc. and Rosen et al.		
<u>V</u>	FP12	WO 03/097660 A1	11/27/2003	Human Genome Sciences, Inc. and Rosen et al.		
	├──		 			ļ
		 		<u> </u>		
 -						
	L	<u> </u>	.1		1	l

504081_1.DOC

IAP34

Examiner Signature	/Celine Qian/	Date Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant, "Applicant's unique citation designation number (optional), "See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04, "Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3), "For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbots as indicated on the document under WIPO Standard ST.16 if possible, "Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and salect option 2.

PTC/SB/088 (07-05)
Approved for use through 07/31/2008, CMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO Complete if Known						
					Application Number	09/921,143	
Ü	7.	SUPPL			Filing Date	August 3, 2001	
]				LOSURE	First Named Inventor	Coleman, Timothy A.	
- 1	SEATE			LICANT	Art Unit	1636	
١,	12 2	(Use as ma	ny sheeis as	necessary)	Examiner Name	Qian, Celine X.	
	Sheet	1	of	5	Attorney Docket Number	1488.100000N/HCC/PAC	
				NON PATENT	LITERATURE DOCUMENT	S	
	Examiner Cite Include name of the author (in California) Initials No. the item (book, magazine, jou			name of the author (in (m (book, magazine, jou	CAPITAL LETTERS), title of the	article (when appropriate), title of etc.), date, page(s), volume issue	L ₃
	CΩ	NPL1			iogenic therapy of proliferative shley Publications Ltd. (March		
		Enholm, B., et al., "Vascular Endothelial Growth Factor-C: A Growth Factor for Lymphatic and Blood," Trends Cardiovascular Med. 8:292-297, Elsevier Science, Inc. (October 1998)					
		NPL3		Ferrara, N., "Vascular Endothelial Growth Factor and the Regulation of angiogenesis," Recent Prog. Hormone Res. 55:15-36, The Endocrine Society (March 2000)			
		NPL4		Halin, C. and Neri, D., "Antibody-Based Targeting of Angiogenesis," Crit. Rev. Ther. Drug Carrier Syst. 18:299-339, Begell House, Inc. (August 2001)			
		NPL5			ogenic therapy: Rationale, chal wer Academic Publishers (De		
		NPL6	monocle	Schlaeppi, JM., et al., "Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor," J. Cancer Res. Clin. Oncol. 125:336-342, Springer-Verlag (May 1999)			
		NPL7	(VEGF)	van der Flier, M., et al., "Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis," J. Neuroimmunol. 160:170-177, Elsevier B.V. (March 2005)			
		NPL8		Walsh, D.A., "Angiogenesis and arthritis," Rheumatology 38:103-112, British Society for Rheumatology (February 1999)			
		NPL9	of an Ar	Winkler, K., et al., "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," J. Immunol. 165:4505-4514, The American Association of Immunologists (October 2000)			
	V	NPL10		ntrez, GenBank Repo ntry date July 1997	ort, Accession No. AF010302,	Mandriota S.J. and Pepper,	

Examiner Signature	/Celine Qian/	Date Considered
0.8.0.00		Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English tanguage Translation is ettached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (07-05)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for	Substitute for form 1449/PTO			Co	Complete if Known		
MUNITE CUIDDI PREDITAT				Application Number	09/921,143		
NINTH SUPPLEMENTAL		Filing Date	August 3, 2001				
	INFORMATION DISCLOSURE			First Named Inventor	Coleman, Timothy A.		
-	STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1636			
			Examiner Name	Qian, Celine X.			
Sheet	2	of	5	Attorney Docket Number	1488.100000N/HCC/PAC		

T.	Non Patent Literature Documents					
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of th		T³				
CÕ	NPLII	Anderson, W.F., "Human gene therapy," Nature 392:25-30, Macmillan Magazines Ltd. (April 1998)				
	NPL12	Borg, JP., et al., "Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase," Oncogene 10:973-984, Stockton Press (March 1995)				
	NPL13	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01AG00811-01, Abstract (January 1994)				
	NPL14	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. 201AG00811-02, Abstract (January 1995)				
	NPL15	Choi, I.H., et al., "Angiogenesis and Mineralization During Distraction Osteogenesis," J. Korean Med. Sci. 17:435-447, The Korean Academy of Medical Sciences (August 2002)				
	NPL16	Copy of Declaration of Dr. Karl Alitalo, In re of: U.S. Application No. 08/585,895, Alitalo et al., filed January 12, 1996, submitted November 26, 1997				
	NPL17	Dias, S., et al., "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," Blood 99:2179-2184, The American Society of Hematology (March 2002)				
	NPL18	English language abstract of JP 64-38100A, cited as document FP2 on Form PTO/SB/08A, Derwent Accession No. 1989-088700/198912				
	NPL19	English language abstract of JP 2-117698 A, cited as document FP3 on Form PTO/SB/08A, Derwent Accession No. 1990-181364/199024				
	NPL20	Fan, TP., et al., "Controlling the vasculare: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy," <i>Trends Pharmaco. Sci. 16</i> :57-66, Elsevier Science Ltd. (February 1995)				
$ \psi $	NPL21	Isner, J.M., et al., "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," Circulation 91:2687-2692, American Heart Association, Inc. (June 1995)				

Examiner		Date
	10-21	
Signature	/Celine Qian/	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	09/921,143	
NINTH SUPPLEMENTAL	Filing Date	August 3, 2001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Coleman, Timothy A.	
STATEMENT BY APPLICANT	Art Unit	1636	
	Examiner Name	Qian, Celine X.	
Core as many specis as necessary) Sheet 3 of 5	Attorney Docket Number	1488.100000N/HCC/PAC	
/			

		Non Patent Literature Documents	
Examiner Cite Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T²
CQ NPL22		Isner, J.M., et al., "Gene therapy for arterial disease," Lancet 344:1653-1654, The Lancet Ltd. (December 1994)	
	NPL23	Isner, J.M., et al., "Physiologic Assessment of Angiogenesis by Arterial Gene Therapy with Vascular Endothelial Growth," J. Cell. Biochem. (Suppl. 21A):378, Abstract C6-215, Wiley-Liss (March-April 1995)	
	NPL24	Isner, J.M., et al., "Therapeutic Angiogenesis in Vascular Medicine," Project No. R01 HL5335401, Abstract (March 1995)	
	NPL25	Kubo, H., et al., "Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblasts growth factor-2-induced lymphangiogenesis in mouse comea," Proc. Natl. Acad. Sci. 99:8868-8873, The National Academy of Sciences (June 2002)	
	NPL26	Kuzuya, M. and Kinsella, J.L., "Induction of Endothelial Cell differentiation In Vitro by Fibroblast-Derived Soluble Factors," Exp. Cell Res. 215:310-318, Academic Press, Inc.(December 1994)	
	NPL27	Maher, P.A., "Stimulation of Endothelial Cell Proliferation by Vanadate Is Specific for Microvascular Endothelial Cells," J. Cell. Physiol. 151:549-554, Wiley-Liss, Inc. (1992)	
	NPL28	Maynard, J. and Georgiou, G., "Antibody Engineering," Annu. Rev. Biomed. Eng. 2:339-376, Annual Reviews (August 2000)	
	NPL29	Mesri, E.A., et al., "Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type I Amplicon Vector Induces Angiogenesis in Mice," Circulation Res. 76:161-167, American Heart Association, Inc. (February 1995)	
	NPL30	Morea, V., et al., "Antibody Modeling: Implications for Engineering and Design," Methods 20:267-279, Academic Press (March 2000)	
Ψ	NPL31	Mulhauser, J., et al., "In Vivo Gene Transfer into Porcine Cardiac Cells with a Replication-Deficient Recombinant Adenovirus Vector," Circulation 88:1-475, Abstract No. 2558, American Heart Association (October 1993)	
		Non Patent Literature Documents	

Examiner /Celine Qian/	Date Considered
--------------------------	--------------------

[&]quot;EXAMINER: Initial It reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1,18. This pollection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pelant and Tradsmark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO				Complete if Known		
	> 1 T > 100 T >	OV:DDY	~~~	IMP A Y	Application Number	09/921,143	
		SUPPL			Filing Date	August 3, 2001	
3				CLOSURE	First Named Inventor	Coleman, Timothy A.	
I	STATE			PLICANT	Art Unit	1636	
	31	(Use as mai	iy sheets a	s necessary)	Examiner Name	Qian, Celine X.	
	Sh	4	of	5	Attorney Docket Number	1488.100000N/HCC/PAC	
3	Examiner Thirials*	Cite No. ¹		m (book, magazine, joun		article (when appropriate), title of c.), date, page(s), volume number, ublished	T²
	CÕ	NPL32	Adeno	user, J., <i>et al.</i> , "VEGF virus Vector Induces A can Heart Association,	Land Expressed by a Replication- Angiogenesis In Vivo," Circula Inc (December 1995)	Deficient Recombinant ation Res. 77:1077-1086,	
		NPL33	Capaci		forms of Platelet-Derived Gro nesis <i>In Vivo</i> ," <i>Biol. Pharm. Bu</i> pan (December 1994)		
		NPL34	tyrosin		ng properties of FLT4, a protect VEGF receptors," Oncogene		
		NPL35			Angiogenic and Proteolytic P Res. 210:298-305, Academic	Properties of Bovine Lymphatic Press, Inc. (February 1994)	
		NPL36		K.H., "From angiogenera, Inc. (February 200)	esis to lymphangiogenesis," Na	at. Med. 7:151-152, Nature	
		NPL37	retinop		H., "New concepts in pathogocrinol. Diabetes 109(Suppl. 2)	enesis and treatment of diabetic):S438-S450, J.A. Barth	
		NPL38			G., "The Vascular Endothelial lopment," <i>Growth Factors 17</i> :	Growth Factor Family: 1-11, Taylor & Francis (1999)	
		NPL39			nesis: potential therapy for isch cience Ltd. (August 1994)	naemic disease," Curr. Opin.	
		NPL40	Arteria	I Gene Transfer of the	Evidence of Enhanced Angiog Plasmid Encoding Vascular E 2565, American Heart Associa	ndothelial Growth Factor,"	
		NPL41	Endoth Model,	elial Growth Factor A	ugments Revascularization in	ntraarterial Bolus of Vascular a Rabbit Ischemic Hind Limb for Clinical Investigation, Inc.	
	\downarrow	NPL42	pVGI.1	(VEGF2) in an Anim	ous Electromechanical Mappin al Model of Chronic Myocard tt Williams & Wilkins (Noven	ial Ischemia," Circulation	

Examiner Signature	/Celine Qian/	Date Considered	

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to eppticant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including galhering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petant and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/68B (07-05)
Approved for use through 07/31/2006. CMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	09/921,143	_
NINTH SUPPLEMENTAL	Filing Date	August 3, 2001	
ENFORMATION DISCLOSURE	First Named Inventor	Coleman, Timothy A.	
ENFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Art Unit	1636	
(Use as many sheets as necessary)	Examiner Name	Qian, Celine X.	
She 5 of 5	Attorney Docket Number	1488.100000N/HCC/PAC	
3-1/			

~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~			
Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T,
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	
CQ	NPL43	Verma, I. and Somia, N., "Gene therapy - promises, problems and prospects," Nature 389:239-242, Macmillan Magazines Ltd. (September 1997)	
	NPL44	Walsh, D.A. and Pearson, C.I., "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," <i>Arthritis Res. 3</i> :147-153, BioMed Central Ltd. (February 2001)	
	NPL45	Williams, R.S., "Southwestern Internal Medicine Conference: Prospects for Gene Therapy of Ischemic Heart Disease," Am. J. Med. Sci. 306:129-136, Lippincott Williams & Wilkins (August 1993)	
	NPL46	Witzenbichler, B., et al., "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," Am. J. Pathol. 153:381-394, American Society for Investigative Pathology, Inc. (August 1998)	
	NPL47	Yeung, P.K.F., "VEGF-2 St Elizabeth's Medical Center," Curr. Opin. Invest. Drugs 2:796-8000, PharmaPress Ltd. (June 2001)	
	NPL48	Letter from John J. Chicca II, Ph.D., Molecular Diagnostic Services, Inc. regarding a third progress report for a project entitled "Cloning and expression of VEGF-2 gene and the efficacy of VEGF-2 protein utilizing the 3-D collagen angiogenesis assay and proliferation," dated February 16, 2006.	
V	NPL49	Letter from John J. Chicca II, Ph.D., Molecular Diagnostic Services, Inc. regarding a fourth progress report for a project entitled "Cloning and expression of VEGF-2 protein utilizing the 3-D collagen angiogenesis assay and proliferation," dated march 14, 2006.	
			<u> </u>
		·	

504074_1.DOC

Examiner Date Celine Qian Considered Signature

EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 609. Draw line through obtation if not in conformance and

*EXAMINER: Initial if reference considered, whether or not obtains is in conformance with MPEP 609. Draw line through citation is not in communication to applicant, include copy of this form with next communication to applicant is unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is stached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.